| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Androgen deprivation therapy use and duration with definitive radiotherapy for localised prostate cancer: an individual patient data meta-analysis
|
Kishan, Amar U
|
|
|
23 |
2 |
p. 304-316
|
artikel
|
| 2 |
An initiative to combat the cancer burden in Uruguay
|
Das, Manjulika
|
|
|
23 |
2 |
p. e61
|
artikel
|
| 3 |
Bone marrow invasion in breast carcinoma
|
Feyaerts, Annelies
|
|
|
23 |
2 |
p. e88
|
artikel
|
| 4 |
Correction to Lancet Oncol 2016; 17: 484–95
|
|
|
|
23 |
2 |
p. e59
|
artikel
|
| 5 |
Correction to Lancet Oncol 2021; 22: 1752–63
|
|
|
|
23 |
2 |
p. e59
|
artikel
|
| 6 |
Correction to Lancet Oncol 2022; 23: 125–37
|
|
|
|
23 |
2 |
p. e59
|
artikel
|
| 7 |
Correction to Lancet Oncol 2022; 23: 270–78
|
|
|
|
23 |
2 |
p. e59
|
artikel
|
| 8 |
Correction to Lancet Oncol 2022; 23: 190–91
|
|
|
|
23 |
2 |
p. e59
|
artikel
|
| 9 |
Dosimetry in radionuclide therapy: the clinical role of measuring radiation dose
|
Lawhn-Heath, Courtney
|
|
|
23 |
2 |
p. e75-e87
|
artikel
|
| 10 |
Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trial
|
Schoenfeld, Jonathan D
|
|
|
23 |
2 |
p. 279-291
|
artikel
|
| 11 |
Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a phase 2 study
|
Siefker-Radtke, Arlene O
|
|
|
23 |
2 |
p. 248-258
|
artikel
|
| 12 |
Equity in cancer drug access in the UK
|
The Lancet Oncology,
|
|
|
23 |
2 |
p. 185
|
artikel
|
| 13 |
Global consequences of the US FDA's accelerated approval of cancer drugs
|
Akhade, Amol
|
|
|
23 |
2 |
p. 201-203
|
artikel
|
| 14 |
Harmonising patient-access programmes: the Dutch DRUG Access Protocol platform
|
Zeverijn, Laurien J
|
|
|
23 |
2 |
p. 198-201
|
artikel
|
| 15 |
Immune checkpoint inhibitors and timing of administration
|
Dizman, Nazli
|
|
|
23 |
2 |
p. e56
|
artikel
|
| 16 |
Immune checkpoint inhibitors and timing of administration
|
O'Brien, Timothy
|
|
|
23 |
2 |
p. e55
|
artikel
|
| 17 |
Immune checkpoint inhibitors and timing of administration – Authors' reply
|
Qian, David C
|
|
|
23 |
2 |
p. e57
|
artikel
|
| 18 |
Immunogenicity and safety of BNT162b2 mRNA vaccine booster in actively treated patients with cancer
|
Ligumsky, Hagai
|
|
|
23 |
2 |
p. 193-195
|
artikel
|
| 19 |
Is non-invasive Cytosponge the holy grail for Barrett's neoplasia?
|
Vieth, Michael
|
|
|
23 |
2 |
p. 190-191
|
artikel
|
| 20 |
Japan resumes active recommendations of HPV vaccine after 8·5 years of suspension
|
Haruyama, Rei
|
|
|
23 |
2 |
p. 197-198
|
artikel
|
| 21 |
MSF breast and cervical cancer screening programmes in Mali and Malawi
|
Devi, Sharmila
|
|
|
23 |
2 |
p. 207-208
|
artikel
|
| 22 |
New EU regulation on health technology assessment of cancer medicines
|
Hwang, Thomas J
|
|
|
23 |
2 |
p. e58
|
artikel
|
| 23 |
Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial
|
Kang, Yoon-Koo
|
|
|
23 |
2 |
p. 234-247
|
artikel
|
| 24 |
Nivolumab plus ipilimumab in melanoma brain metastases
|
Rizzo, Alessandro
|
|
|
23 |
2 |
p. e52
|
artikel
|
| 25 |
Nivolumab plus ipilimumab in melanoma brain metastases
|
Di Giacomo, Anna Maria
|
|
|
23 |
2 |
p. e53
|
artikel
|
| 26 |
Nivolumab plus ipilimumab in melanoma brain metastases – Authors' reply
|
Tawbi, Hussein A
|
|
|
23 |
2 |
p. e54
|
artikel
|
| 27 |
Omicron: NHS agrees 3-month deal with private sector to provide cancer care backup
|
Wilkinson, Emma
|
|
|
23 |
2 |
p. e60
|
artikel
|
| 28 |
Overcoming immunotherapy resistance in NSCLC
|
MacManus, Michael
|
|
|
23 |
2 |
p. 191-193
|
artikel
|
| 29 |
Patient-reported outcomes with first-line nivolumab plus cabozantinib versus sunitinib in patients with advanced renal cell carcinoma treated in CheckMate 9ER: an open-label, randomised, phase 3 trial
|
Cella, David
|
|
|
23 |
2 |
p. 292-303
|
artikel
|
| 30 |
Promising outlook with sugemalimab in non-small-cell lung cancer
|
Rosell, Rafael
|
|
|
23 |
2 |
p. 186-188
|
artikel
|
| 31 |
Safety of adjuvant CDK4/6 inhibitors during the COVID-19 pandemic
|
Pfeiler, Georg
|
|
|
23 |
2 |
p. 195-197
|
artikel
|
| 32 |
Should radiotherapy be considered for the initial treatment of brain metastases?
|
Minniti, Giuseppe
|
|
|
23 |
2 |
p. 205-206
|
artikel
|
| 33 |
Sugemalimab versus placebo after concurrent or sequential chemoradiotherapy in patients with locally advanced, unresectable, stage III non-small-cell lung cancer in China (GEMSTONE-301): interim results of a randomised, double-blind, multicentre, phase 3 trial
|
Zhou, Qing
|
|
|
23 |
2 |
p. 209-219
|
artikel
|
| 34 |
Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): interim and final analyses of a double-blind, randomised, phase 3 clinical trial
|
Zhou, Caicun
|
|
|
23 |
2 |
p. 220-233
|
artikel
|
| 35 |
Targeting HER2 for localised oesophageal cancer
|
Lordick, Florian
|
|
|
23 |
2 |
p. 188-190
|
artikel
|
| 36 |
Thank you to The Lancet Oncology's clinical and statistical peer reviewers in 2021
|
The Lancet Oncology Editors,
|
|
|
23 |
2 |
p. e45-e51
|
artikel
|
| 37 |
Theranos: the proof that public regulation matters
|
Furlow, Bryant
|
|
|
23 |
2 |
p. 204
|
artikel
|
| 38 |
Therapeutic avenues for cancer neuroscience: translational frontiers and clinical opportunities
|
Shi, Diana D
|
|
|
23 |
2 |
p. e62-e74
|
artikel
|
| 39 |
Trastuzumab with trimodality treatment for oesophageal adenocarcinoma with HER2 overexpression (NRG Oncology/RTOG 1010): a multicentre, randomised, phase 3 trial
|
Safran, Howard P
|
|
|
23 |
2 |
p. 259-269
|
artikel
|
| 40 |
Use of a Cytosponge biomarker panel to prioritise endoscopic Barrett's oesophagus surveillance: a cross-sectional study followed by a real-world prospective pilot
|
Pilonis, Nastazja Dagny
|
|
|
23 |
2 |
p. 270-278
|
artikel
|
Tijdschrift beschrijving